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Purpose: Locally synthesized growth hormone (GH) may act as a survival factor in several tissues. Experimental studies
with chick retinal ganglion cells (RGCs) suggest that GH, synthesized within the developing retina, may have autocrine
or paracrine roles in the regulation of the waves of cell death characteristic of RGC differentiation. There is also evidence
that GH may have a similar neuroprotective function in the rat retina, however, there is no information concerning such
a role in the human retina. In this paper we extended our earlier work by determining whether the local expression of
retinal GH correlates with RGC apoptosis in human retinas.
Methods: In the absence of experimental approaches to survival factor function in the human retina, we have used a
correlative immunocytochemical technique to determine how the expression of GH relates to cell death in RGCs. We used
sections of human retinas, taken postmortem, that we double-labeled for GH and apoptotic cell death using terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL).
Results: We found that approximately 35% of cells in the ganglion cell layer (GCL) were both GH positive and GH
receptor (GHR) positive, and that GH colocalized with GHR in these cells. However, none of the apoptotic cells in the
GCL were GH immunoreactive. Labeling of sections with the RGC marker, synuclein, indicated that at least 95% of the
cells in the GCL were RGCs, leading us to conclude that the majority of the cells that we have examined in the GCL are
RGCs.
Conclusions: The results are consistent with the earlier proposal, based on in vivo and in vitro experimental chick embryo
studies, that GH promotes survival in adult human RGCs.
We have previously shown that growth hormone (GH) is
present in the retina and vitreous of the developing chick
embryo [1], in perinatal and adult rats [2], and in the adult
human [3]. In these tissues, GH is synthesized in the retinal
ganglion cells (RGCs) from where it is secreted and stored in
the vitreous [4]. During chick embryo development, this GH
appears  in  the  retina  and  vitreous  before  the  functional
differentiation of the pituitary gland, and it appears to act
locally in the retina as an autocrine or paracrine growth and
differentiation factor promoting cell survival [5,6]. Like other
paracrine growth factors, which act during development [7],
GH  appears  to  activate  specific  intracellular  antiapoptotic
signaling pathways in the RGCs leading to cell survival [8,
9].  It  is  thus  thought  that  retinal  GH  is  an  endogenous
neuroprotective  agent  that  may  regulate  programmed  cell
death in the developing retina [10].
Since  GH  is  present  in  adult  human  and  mammalian
retinas [2,3], we have sought to determine whether there is
any evidence that GH might also be neuroprotective in human
RGCs in which it is present. This is of potential significance
since glaucoma is a disease of RGC degeneration in the elderly
[11], which may be ameliorated by exogenous neurotrophic
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factors  such  as  brain-derived  neurotrophic  factor  (BDNF
[12]). A positive correlation between the presence of GH and
RGC  survival  might  therefore  provide  a  rationale  for
considering  GH  as  a  possible  therapeutic  RGC
neuroprotective agent.
In the present study, we have examined sections of human
retinas for the presence of GH in the cells of the RGC layer,
and correlated this with the occurrence of RGC death using
the method of terminal deoxynucleotidyl transferase dUTP
nick end-labeling (TUNEL). We found that none of the cells
in the ganglion cell layer (GCL) that expressed GH were
TUNEL-positive, suggesting that the presence of GH in the
RGCs is likely involved in the promotion of cell survival.
METHODS
Paraffin  wax-embedded  sections  of  human  retinas,  taken
postmortem, were obtained from Dr. Yeni Yucel, Department
of Ophthalmology and Vision Sciences, University of Toronto
(Toronto,  Ontario).  Experiments  were  performed  after
approval  by  the  Health  Research  Ethics  Board  of  the
University of Alberta. The formalin-fixed specimens used in
this study were taken from three different cadavers: a 74-year-
old male (cause of death: myocardial infarction; specimen
fixed 11 h postmortem); an 81-year-old male (cause of death:
myocardial infarction; specimen fixed 2 h postmortem); and
a  69-year-old  male  (cause  of  death:  amyotrophic  lateral
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920sclerosis; specimen fixed 13 h postmortem). Results were
consistent between sections from each of these individuals.
For immunocytochemical double labeling, the sections
were dewaxed and blocked for 1 h in 3% BSA (BSA) and then
incubated overnight, at 4 °C, with a 1:200 dilution of rabbit
anti-human  GH  (provided  by  Dr.  A.  F.  Parlow,  National
Hormone and Peptide Program, Torrance, CA), followed by
a  2  h  incubation  in  a  1:200  dilution  of  goat-anti-rabbit
secondary antibody that was conjugated to Alexa-Fluor 488
(green; Invitrogen, Carlsbad, CA). All washings mentioned in
this paragraph were done in phosphate buffered saline (PBS).
The  PBS  contained:  NaCl,  7.2  g/l;  Na2HPO4,  1.48  g/l;
KH2PO4, 0.43 g/l. After washing, sections were then incubated
overnight in 30 μg/ml Mab 263, a mouse anti-human GH
receptor (GHR) monoclonal antibody (AbCam, Cambridge,
MA). Sections were then washed and incubated for 2 h with
1:200  goat-anti-mouse  Alexa  Fluor  594  (red;  Invitrogen).
After  washing,  sections  were  then  incubated  with  4’,  6’-
diamino-2-phenylindole (DAPI) for 2 min to stain nuclei. The
labeled  sections  were  then  examined  by  a  confocal
microscope  (Model  LSM  510;  Carl  Zeiss  Canada  Ltd.,
Toronto,  Ontario),  equipped  with  appropriate  lasers.  In
negative controls, the two primary antibodies were replaced
with non-immune rabbit serum and mouse IgG. The primary
antibodies  have  been  used  previously  for  GH  and  GHR
localization in human tissues [3,13,14].
To confirm the identity of cells in the GCL, we used C-20
(Santa  Cruz  Biotechnology  Inc.,  Santa  Cruz,  CA),  a
polyclonal  antibody,  against  γ-synuclein  [15,16].  This
antibody  was  used  at  a  dilution  of  1:50  for  2  h  at  room
temperature,  and  its  specificity  was  confirmed  by  pre-
absorption with the blocking peptide (C-20P) supplied by the
company.  Double  labeling  for  GH  and  synuclein  was
performed by initially incubating sections overnight in GH
antiserum followed by incubation with anti-synuclein.
For the TUNEL technique, sections were dewaxed and
washed  in  PBS  before  they  were  treated  with  2.5  μg/ml
proteinase K for 10 min at room temperature. Sections were
then treated for 5 min with a TdT buffer that consisted of
30 mM Trizma base, 140 mM sodium cacodylate, and 1 mM
cobalt  chloride  (pH  7.2).  Tissue  was  incubated  with  the
reaction mixture for 1.5 h at 37 °C in a humid chamber, using
the kit from Roche Molecular Biochemicals (Laval, Quebec)
at a volume of 20 μl per sample. A volume of 100 μl contained:
double  distilled  water,  81  μl;  TdT  buffer,  6.5  μl;  cobalt
chloride, 3.26 μl; biotin-16-dUTP stock, at a concentration of
1 nmol/µl, 1.86 μl; dUTP, 5.5 μl; and TdT, at a concentration
of 10 units/μl, 2 μl. Samples were then washed in PBS three
times for 5 min each, and blocked with 3% skimmed milk in
PBS containing 0.5% Tween-20 for 30 min. Samples were
washed  in  PBS  three  times  for  5  min  each,  and  the
fluorochrome,  Streptavidin-FITC,  was  added  at  a
concentration of 1:200, for 1 h at room temperature. Following
3 washes in PBS for 10 min each, the samples were taken
through the immunocytchemistry procedure described above,
using  Alexa-Fluor  594  as  the  secondary  antibody,  and
mounted  on  slides  with  Vectashield  (Vector  Laboratories
Canada  Inc.,  Burlington,  Ontario).  All  cell  counting  was
performed by manually counting each cell seen in the confocal
images. All images of the retina were obtained from within
approximately 5 mm of the optic nerve head. Sample sizes (n)
are  the  combined  numbers  of  cells  from  all  three  retina
samples.
RESULTS
Immunocytochemical localization of GH and GHR in human
retina sections (Figure 1) indicates that both are preferentially
located in cells of the GCL, where they colocalized (yellow,
in the merged image) in the nucleus as well as cytoplasm of
many cells. Little or no GH was expressed in other cell layers.
Analysis of the numbers of GH-positive or GHR-positive cells
in the GCL from three different retina samples indicated that,
overall, approximately 35% of cells in the GCL were GH-
positive (n=56 cells), while a somewhat smaller number were
GHR-positive. Because the GHR signal was weaker than the
GH signal, the apparently lower number of GHR-positive
cells may be due to the lower sensitivity of the technique. Cells
of the inner and outer nuclear layers (Figure 1) were not
immunoreactive  for  GH  or  GHR.  When  the  primary
antibodies  were  replaced  with  rabbit  serum  (for  GH
antiserum)  or  mouse  IgG  (for  GHR  antiserum),  the
immunoreactivity was abolished (Figure 2A).
To confirm the identity of cells in the GCL, we labeled
sections with an antibody against γ-synuclein, a marker for
RGCs  [15,16].  The  majority  of  cells  in  the  GCL  were
preferentially  labeled  by  this  antibody,  largely  in  the
cytoplasm (Figure 2B). DAPI labeling was used as a cell
marker of all cells. At least 95% (n=200 cells) of the cells in
the GCL were labeled by this antibody. When the blocking
peptide  supplied  by  the  manufacturer  was  added  to  the
antibody  before  its  use,  immunoreactivity  was  abolished.
Double labeling sections for γ-synuclein (red) and GH (green)
showed that GH was localized to RGCs (Figure 3; asterisks).
Double labeling cells with GH and TUNEL for apoptotic
DNA  fragmentation  (Figure  4)  showed  that  positive
immunoreactivity for GH always correlated with the absence
of TUNEL labeling. Overall, based on three different retina
samples, 46.4% of cells in the GCL were TUNEL-positive
(n=56 cells). Of these, 100% were GH-negative (n=35 cells).
Of  the  remaining  TUNEL-negative  cells,  32%  were  GH-
negative (n=48 cells).
In Figure 4, it can be seen that cells labeled A5, B2, C1,
D2, and D4 (asterisks) are all GH-positive (red) and TUNEL-
negative (red nuclei in the merged images). By contrast, cells
A2, A4, B1, B4, B5, C2, D1, and D3 are TUNEL-positive
(green) but GH-negative (blue-green nuclei in the merged
Molecular Vision 2009; 15:920-926 <http://www.molvis.org/molvis/v15/a96> © 2009 Molecular Vision
921images).  Approximately  18%  of  cells  are  both  TUNEL-
negative  and  GH-negative  (A1,  A3,  and  B3;  blue  in  the
merged images).
DISCUSSION
There are limited experimental options available for use in
attempts to establish a functional role for endogenous GH in
adult human RGCs. In this study, we chose to correlate the
presence of immunoreactive GH with a marker of cell death
in the GCL from sectioned human retinas. We found that cells
of  the  GCL  that  contained  TUNEL-positive  nuclei  never
expressed  GH  immunoreactivity  in  their  nucleus  or
cytoplasm. Of the remaining cells that contained TUNEL-
negative nuclei, two-thirds had GH in the cytoplasm as well
as nuclei. Labeling of sections with the RGC marker synuclein
[15,16], indicated that at least 95% of the cells in the GCL
were RGCs, leading us to conclude that the majority of the
cells that we have examined in the GCL are RGCs and not
cells displaced from other layers of the retina [17]. This result
therefore  provides  us  with  circumstantial  evidence  that
endogenous GH in human RGCs may have a role in cell
survival, and is consistent with our previous experimental
studies on chick RGCs showing that GH has anti-apoptotic
properties  both  in  vivo  and  in  vitro  in  these  cells  during
development [6,8,9].
One third of the TUNEL-negative RGCs apparently did
not express GH. We conclude that GH is sufficient, but not
necessary, for RGC survival. Presumably, such cells may
receive survival signals from other molecules, since GH is by
Figure 1. A human retina section immunocytochemically labeled for GH and GHR. A: DAPI labeling (blue) shows the position of all nuclei
in the section. B: Growth hormone (GH) antiserum (green) labels cells in the ganglion cell layer (GCL). C: GH receptor (GHR) antibodies
(red) label cells in the GCL. D: When panels B and C are merged, it is clear that GH and GHR are co-localized in the same cells (yellow).
Abbreviations: inner nuclear layer (INL); outer nuclear layer (ONL). Scale bar equals 40 μm.
Molecular Vision 2009; 15:920-926 <http://www.molvis.org/molvis/v15/a96> © 2009 Molecular Vision
922no means the only neuroprotective molecule present in the
retina [18].
We found that 46% of the cells in the GCL of our samples
were TUNEL-positive. This number of apoptotic cells may be
attributed not only to natural cell death in this layer, but also
possibly  to  postmortem  cell  death,  since  fixation  of  the
specimens was performed between 2 and 13 h postmortem.
However, evidence from examination of retinas after optic
nerve transection [19] indicates that RGCs survive for several
days after this insult. It is likely that GH is able to rescue RGCs
irrespective of the cause of cell death in the GCL, whether
owing to disease or whether it is post-mortem, since our in
Figure  2.  Human  retina  sections
showing  an  immunocytochemical
control  and  γ-synuclein  labeling.  A:
This  image  shows
immunocytochemical  labeling  of  a
section in which growth hormone (GH)
antiserum was replaced by rabbit serum
and GH receptor (GHR) antibodies were
replaced by mouse IgG. DAPI labeling
(blue) shows the position of all nuclei in
the section. B: This is an oblique section
through  the  retina,  labeled  with  an
antibody against γ-synuclein (green) to
identify retinal ganglion cells (RGCs) in
the  ganglion  cell  layer  (GCL).  The
majority  of  cells  in  the  GCL  show
cytoplasmic  labeling  for  synuclein.
DAPI labeling (blue) shows the position
of  all  nuclei  in  the  section.
Abbreviations:  inner  nuclear  layer
(INL); outer nuclear layer (ONL). Scale
bar equals 40 μm.
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923vitro results with chick RGCs show that GH is also able to
protect these cells from apoptosis after axotomy [19] that is
performed to culture the cells [6,8,9].
That GH and GHR are mostly colocalized to the nuclei is
not unexpected; it has long been known that both GHR and
GH are associated with the nucleus [20]. Technically, we
performed the more complex TUNEL procedure before the
immunocytochemistry. In contrast to GH, immunoreactivity
for GHR did not survive the TUNEL procedure, presumably
because  of  the  weaker  immunoreactivity  of  GHR  in
comparison with GH. It is unlikely that the TUNEL procedure
inhibits subsequent GH immunoreactivity, because the GH
immunoreactivity clearly survives the proteinase-K treatment
(compare cell A4 with A5; and B1 with B2), which is the only
step in the TUNEL procedure likely to interfere with GH
immunoreactivity.
On the basis of these results, the question arises as to
whether  or  not  patients  with  low  systemic  GH  levels
experience retinal cell death or other retinopathies. Bearing in
mind that systemic levels of pituitary GH may not be relevant
to the ocular levels of locally produced GH [7], the literature
suggests  that  such  patients  may  indeed  exhibit  ocular
Figure  3.  A  human  retina  section
double-labeled for γ-synuclein and GH.
A: γ-synuclein antibodies (red) label a
retinal  ganglion  cell  (RGC)  in  the
ganglion cell layer (GCL). B: growth
hormone (GH) antiserum (green) labels
a nucleus in the GCL. C: The merged
image of panels A and B shows that GH
localizes to the same cell as γ-synuclein,
an RGC marker, (asterisks) indicating
that this GH-containing cell is an RGC.
DAPI labeling (blue) shows the position
of  all  nuclei  in  the  section.
Abbreviations:  ganglion  cell  layer
(GCL); inner nuclear layer (INL). Scale
bar equals 20 μm.
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924dysfunction  [21].  Dysfunctions  related  to  GH  deficiency
include: reduced retinal vascularization, optic disc and optic
nerve hypoplasia, Jacobsen syndrome, Cockayne syndrome,
and a rare form of retinitis pigmentosa (RHYNS syndrome)
characterized by hypopituitarism, GH deficiency, and skeletal
dysplasia [21].
Conclusion: We conclude that in the human retina, the
presence of GH in the RGCs correlates with the survival of
these cells. This conclusion is consistent not only with our
previous experimental results [6,8,9], but also with a growing
literature  indicating  the  general  anti-apoptotic  and
neuroprotective  effects  of  GH  [22]  in  diverse  cell  types
including:  myoblasts  [23],  myocytes  [24],  neonatal  brain
neurons [25], and cells of the immune system [26].
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